The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
Company to launch product after the expiry of semaglutide patent in India
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
DNA nanorobots—tiny, self-assembling machines capable of detecting diseases in blood samples within 2–4 hours
Over 8.8?million Indians aged 60 and above currently live with dementia,
India in the Changing Landscape of Life-Sciences Research & Development
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
Subscribe To Our Newsletter & Stay Updated
